Agilent Ventures has taken part in a Novo Growth-led round that brought the precision medicine technology developer's overall funding to more than $120m.

Amid the covid-19 pandemic, interest in life sciences is now perhaps at its highest. This is true in corporate venture capital and three of the multimillion-dollar stories we reported in mid-August corroborate this.

Kunlun Tech returned to reinvest in a $21.6m round for the cardiovascular imaging system provider, which is also working on a device for coronavirus diagnosis.

Boehringer Ingelheim Venture Fund led an $11.2m series A round for Bodyport, developer of a cardiovascular disease detection system.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Eberhard Karls University of Tübingen's messenger RNA drug developer CureVac priced the offering at the top of its range.

GlaxoSmithKline Eli Lilly and Genmab-backed messenger RNA drug developer CureVac priced the offering at the top of its range.

The fungal disease drug developer pulled in $60.8m from investors including Novo, which is switching board members at the company.

Carillon Clinics and Maccabi Healthcare Service have contributed to the $150m raised by the medical technology fund as anchor investors.

The healthcare automation software developer has now raised $70m altogether, with Optum Ventures leading its latest round.